Could a prostate cancer imaging agent help spot aggressive breast cancer?
NCT ID NCT06586047
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing whether a special PET scan tracer, originally used for prostate cancer, can detect metastatic triple negative breast cancer. Thirty women with advanced disease will receive both standard FDG PET and the new PSMA PET scan. The goal is to see if PSMA shows up on tumors, which could later allow for targeted treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18 F-DCFPyL (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could identify patients who might benefit from PSMA-targeted therapies, offering a new treatment path for triple negative breast cancer.
What could go wrong
This is a very early, small study (30 people) focused on imaging, not treatment. It may not show enough PSMA activity to justify future therapy trials, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Healthcare
RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••